so, what exactly
is her2?
first, let’s talk
about biomarkers
HER2 is a type of biomarker. Biomarkers can show us whether processes in the cell are working the way they should. And they can help doctors understand how other metastatic solid tumors like metastatic bladder cancer may progress and how they might respond to treatment.
Normally, HER2 is a protein that helps
cells grow and repair themselves.
But too much HER2 may cause
cells to grow uncontrollably and
become cancerous.
The amount of HER2 on the surface
of cancer cells helps to determine
someone's HER2 status.
HER2 matters in
METASTATIC
bladder
cancer
HER2 matters in
METASTATIC
bladder
cancer
When high levels of HER2 are present, it can mean the cancer is more aggressive. That’s why knowing your HER2 status is important. It may change the way your cancer is treated.
High levels of HER2 can be found in up to 56% of people with metastatic bladder cancer.
do you know
your her2 status?
Ask to get tested.
Your doctor can perform a biopsy, which takes a small sample of your tumor to see if you’re HER2-positive. If you’ve already had one, you can ask your doctor to reexamine a sample from an existing biopsy. If you haven’t had a biopsy, your doctor can perform one to confirm your HER2 status.
Okay, what happens next?
If the test shows that you’re HER2-positive, your doctor may recommend a targeted treatment plan that’s fine-tuned to your cancer.
Ask for another look at your biopsy.
Even if you’ve been tested before, there might be more to your HER2 status than you previously thought.
Ask your doctor to reexamine your biopsy results to ensure that you know your HER2 status is up-to-date.
Don’t let the conversation slip your mind. Talking to your doctor about your HER2 status may help shape personalized care.
now you know your
her2 status matters
and so do your
options
Discover how your HER2 status may change your metastatic bladder cancer plan
Not an actual patient.
Hear About HER2
Learn why others
believe HER2 status
matters
Dr neal shore, a medical oncologist specializing in bladder cancer, discusses why HER2 status matters